functioning post intervention (N=1,449; SMD=0.506; 95%CI=0.347, 0.665; p<.001). Improvements in global symptoms (N=849; SMD=-0.297; 95%CI=-0.484, -0.111; p=.002) and positive symptoms (N=784; SMD=-0.227; 95%CI=-0.416, -0.038; p=.018) were also found. Compensatory interventions were not associated with improvements in negative symptoms (N=736; 0.058; p=.150). The heterogeneity of findings was low. Discussion: Compensatory approaches are effective for improving functioning in psychosis, with a medium effect size. General symptoms and positive symptoms appear to benefit from compensatory approaches, but compensatory approaches are not effective for improving negative symptoms. Future analyses will examine the durability of effects, effects of study quality and moderating factors such as pure vs. partially compensatory, treatment intensity/length, mode of delivery (group vs. individual), baseline functioning level and age of participants. 
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NIMHANS, Bengaluru
Background: Up to 25% of schizophrenia patients continue to experience distressing auditory hallucinations despite best efforts at treatment with antipsychotic drugs. Transcranial direct current stimulation (tDCS) has been suggested to rapidly attenuate such persistent hallucinations. Methods: We treated 23 schizophrenia patients with persistent, antipsychotic-refractory auditory hallucinations using tDCS in a single-group, open-label design. tDCS was administered at 2 mA current intensity for 20 min, twice-daily and 4 h apart, across 5 consecutive days; the anode was placed over the the left dorsolateral prefrontal cortex and the cathode over the left temporoparietal junction. Ongoing antipsychotic medications were continued unchanged. Patients were assessed using the Auditory Hallucinations Rating Scale (AHRS) at treatment endpoint and at 1-and 3-month follow up. Response was defined as 50% or greater attenuation in AHRS scores. Results: All patients completed the study. tDCS resulted in substantial improvement. Mean (standard deviation) AHRS scores dropped from 29.0(8.3) at baseline to 4.4(5.6) at treatment endpoint; these values were 9.3(9.3) and 7.8(8.4) at 1-and 3-months follow up. The response rate was 91.3%, 69.6%, and 82.6% at the 3 posttreatment assessment points, respectively. Complete remission of hallucinations (AHRS=0) was observed in 61%, 44%, and 44% at the 3 posttreatment assessment points. tDCS was very well tolerated and adverse effects were minimal. Discussion: tDCS is effective and well tolerated in schizophrenia patients with persistent, antipsychotic-refractory auditory hallucinations. In most patients, the benefits last for up to 3 months or longer. Background: Evidence till date shows different reasons of relapse in schizophrenia around the world. However, there was almost no reliable data from Nepal. We want to report a thematic study based on the reports of 12 patients living with schizophrenia and their family members. These patients were approached during psychoeducation group sessions. Methods: Twelve patients with a diagnosis of schizophrenia as per Diagnostic and Statistical Manual of mental disorders-5 criteria, who were accompanied by their family members were selected. A minimum
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